Information Provided By:
Fly News Breaks for November 30, 2015
GWPH
Nov 30, 2015 | 07:58 EDT
Roth Capital analyst Elemer Piros re-initiated GW Pharmaceuticals with a Buy rating and $130 price target. The analyst believes peak sales potential of Epidiolex could approach $3B.
News For GWPH From the Last 2 Days
There are no results for your query GWPH